Sexual Health Testing Market Size & Growth Forecast 2027–2036, By Segments (Device Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Sexual Health Testing Market size was over USD 107.35 Billion in 2026 and is likely to grow at 5.62% CAGR between 2027 and 2036, reaching USD 185.47 Billion by 2036. The industry revenue for 2027 is estimated at USD 112.47 Billion.

• Base Year Value (2026): USD 107.35 Billion
• CAGR (2027-2036): 5.62%
• Forecast Year Value (2036): USD 185.47 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Sexual Health Testing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads through advanced healthcare infrastructure, broad diagnostic access, established screening practices, and growing emphasis on early STI detection and preventive care.
  • Asia Pacific is gaining momentum from improving healthcare access, expanding diagnostic infrastructure, rising awareness, and stronger public health emphasis on early detection.

• Segment Momentum:

  • Laboratory devices accounted for 64.03% share in 2025 due to their high-throughput capabilities, testing accuracy, and use across hospitals, laboratories, and specialized facilities.
  • Point of care devices are growing fastest as providers increasingly adopt rapid, decentralized testing solutions that enable quicker diagnosis and immediate treatment decisions.

• Market Expansion Drivers:

  • Rising prevalence of sexually transmitted diseases increasing demand for diagnostic testing services
  • Government-led awareness and screening programs improving early detection of sexual health conditions
  • Advancements in rapid and at-home diagnostic kits expanding accessibility of STD testing solutions

• Leading Market Participants:

  Prominent companies in the sexual health testing market include Abbott Laboratories (United States), Hologic Inc. (United States), bioMérieux SA (France), OraSure Technologies Inc. (United States), Roche Holding AG (Switzerland), Thermo Fisher Scientific Inc. (United States), Qiagen N.V. (Germany), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (United States)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 107.35 Billion
  • 2027 Estimated Market Size: USD 112.47 Billion
  • Projected Market Size: USD 185.47 Billion by 2036
  • Growth Forecasts: 5.62% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Laboratory Devices (Device Type) | Diagnostic Centers (End-use) | Chlamydia (Application)
  • Emerging Opportunity Segment: Point of Care (PoC) Devices (Device Type) | Diagnostic Centers (End-use) | HIV/AIDS (Application)

Market Growth Drivers and Industry Trends

Rising prevalence of sexually transmitted diseases increasing demand for diagnostic testing services

The increasing incidence of sexually transmitted diseases is creating greater demand for timely diagnosis and treatment, which will drive the sexual health testing market growth across healthcare systems. Rising awareness of the health consequences associated with untreated infections has encouraged individuals to seek routine screening and diagnostic services, particularly among populations at elevated risk. Healthcare providers are also placing greater emphasis on early identification to reduce disease transmission, improve patient outcomes, and support appropriate treatment decisions. This growing need for accurate and accessible diagnostic services has expanded the role of specialized testing facilities, hospitals, and community healthcare centers.

Government-led awareness and screening programs improving early detection of sexual health conditions

Public health initiatives focused on education and preventive care are encouraging broader participation in screening programs, and the sexual health testing market is gaining momentum as governments strengthen efforts to promote early diagnosis. Awareness campaigns help reduce stigma surrounding sexual health while informing communities about the importance of routine testing and timely medical intervention. Expanded screening services through public healthcare facilities, educational institutions, and community outreach programs have improved access to diagnostic testing for a wider population. These initiatives also support disease surveillance efforts by enabling healthcare authorities to identify infection patterns and implement targeted prevention strategies.

Advancements in rapid and at-home diagnostic kits expanding accessibility of STD testing solutions

Innovations in diagnostic technology are making sexual health testing more convenient and widely accessible, which will boost the sexual health testing market demand by addressing barriers associated with traditional laboratory-based testing. Rapid diagnostic kits and at-home testing solutions enable individuals to obtain results more quickly while offering greater privacy and convenience, encouraging more people to participate in routine screening. Improvements in test accuracy, user-friendly sample collection methods, and streamlined reporting processes have increased confidence in these solutions among both healthcare providers and consumers. The availability of flexible testing options also supports earlier diagnosis in populations that may have limited access to conventional healthcare facilities.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of sexually transmitted diseases increasing demand for diagnostic testing services	2.6%	High	North America, Europe	High	Near Term
Government-led awareness and screening programs improving early detection of sexual health conditions	2.4%	High	Europe, Asia Pacific	High	Near Term
Advancements in rapid and at-home diagnostic kits expanding accessibility of STD testing solutions	2.8%	High	North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America dominated the sexual health testing market in 2026, supported by advanced healthcare infrastructure, broad access to diagnostic services, and growing awareness of sexually transmitted infections and preventive healthcare. Established screening practices, increasing emphasis on early detection, and the availability of convenient laboratory and point-of-care testing options are strengthening demand. Greater acceptance of routine sexual health screening and expanding access to confidential diagnostic services are also supporting market development.

Asia Pacific is anticipated to experience the fastest growth, driven by improving healthcare access, rising awareness of sexual health, and expanding diagnostic infrastructure. Growing public health emphasis on early detection, increasing availability of testing services, and greater consumer willingness to seek preventive screening are creating favorable conditions for market expansion. The development of accessible diagnostic facilities across emerging economies is further expected to improve testing adoption.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Device Type Segment Analysis: Laboratory Devices (Largest Segment) vs Point of Care (PoC) Devices (Fastest-Growing Segment)

The laboratory devices segment dominated the sexual health testing market, accounting for the largest share of 64.03% in 2026. Its leadership is driven by the widespread adoption of high-throughput diagnostic platforms capable of delivering accurate and comprehensive testing for a broad range of sexually transmitted infections. Hospitals, diagnostic laboratories, and specialized testing facilities continue to rely on laboratory-based systems due to their ability to process large sample volumes, support confirmatory testing, and integrate advanced molecular diagnostic techniques. Continuous improvements in automation and laboratory workflow efficiency further reinforce the segment's leading position.

The point of care (PoC) devices segment is experiencing the fastest growth as healthcare providers increasingly prioritize rapid diagnosis and immediate clinical decision-making. Growing demand for decentralized testing, expanding community-based screening programs, and the need to improve access to sexual health services are accelerating the adoption of portable diagnostic devices. Their ability to deliver timely results with minimal infrastructure requirements supports earlier treatment initiation and strengthens disease management across diverse healthcare settings.

End-use Segment Analysis: Diagnostic Centers (Largest & Fastest-Growing Segment)

Holding the largest share of 55.12% in 2026, the diagnostic centers segment led the sexual health testing market due to its specialized testing capabilities, broad test portfolios, and established laboratory infrastructure. Diagnostic centers serve as primary testing hubs for routine screening, confirmatory analysis, and preventive healthcare programs, attracting a large patient base seeking reliable and confidential services. Increasing awareness of sexually transmitted infections, greater emphasis on early detection, and expanding availability of advanced diagnostic technologies continue to support patient volumes. As demand for accessible and efficient testing services grows, diagnostic centers are well positioned to remain both the largest and fastest-growing end-use segment.

Application Segment Analysis: Chlamydia (Largest Segment) vs HIV/AIDS (Fastest-Growing Segment)

The chlamydia segment held the largest share in 2026, supported by the high demand for routine screening, particularly among sexually active populations and individuals participating in preventive healthcare programs. Clinical guidelines emphasizing early identification and timely treatment, together with expanding public health initiatives, have sustained consistent testing volumes for chlamydia across hospitals, clinics, and diagnostic laboratories.

In the sexual health testing market, the HIV/AIDS segment is emerging as the fastest-growing application owing to continued efforts to expand early diagnosis, improve linkage to care, and strengthen routine screening initiatives. Greater availability of rapid testing technologies, increasing public awareness campaigns, and broader integration of HIV testing into primary healthcare services are contributing to rising adoption and reinforcing the segment's growth trajectory.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Device Type	Laboratory Devices, Point of Care (PoC) Devices	Laboratory Devices	Point of Care (PoC) Devices
End-use	Hospitals, Diagnostic Centers, Others	Diagnostic Centers	Diagnostic Centers
Application	Chlamydia, Gonorrhoea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS	Chlamydia	HIV/AIDS

Competitive Landscape and Market Positioning

Top players in the sexual health testing market:

1. Abbott Laboratories (United States)
2. Hologic, Inc. (United States)
3. bioMérieux SA (France)
4. OraSure Technologies, Inc. (United States)
5. Roche Holding AG (Switzerland)
6. Thermo Fisher Scientific, Inc. (United States)
7. Qiagen N.V. (Germany)
8. Siemens Healthineers AG (Germany)
9. Becton Dickinson and Company (United States)

The sexual health testing market is experiencing a shift toward more accessible and user-centric diagnostic solutions, intensifying competition among providers seeking to improve convenience, accuracy, and privacy. Demand for decentralized testing approaches is encouraging market participants to refine product designs and expand testing accessibility beyond conventional healthcare settings. Competitive differentiation is increasingly influenced by the ability to combine dependable diagnostic performance with simplified user experiences and broader adoption pathways.

Industry Development/News

Company Name	Date	Key Development
Birmingham LGBT	Jan-26	Birmingham LGBT inaugurated a purpose-built facility within Birmingham's Gay Village, materially scaling regional capacity for targeted healthcare delivery. The infrastructure investment expands the organization's operational footprint to enhance community-based access to specialized sexual health and support services.
Visby Medical	Nov-25	Visby Medical broadened its diagnostic portfolio with the introduction of an at-home PCR-based STI testing solution capable of delivering laboratory-quality results within 30 minutes. This innovation advances decentralized testing capabilities, facilitating rapid self-administered diagnostics outside traditional clinical environments and altering consumer access models.
Nova Scotia Health	Aug-24	Nova Scotia Health introduced Atlantic Canada's first take-home STI testing kit, utilizing a self-collection framework to expand regional access to sexual health diagnostics. This operational deployment is structured to minimize screening barriers and increase diagnostic reach through decentralized sample collection alternatives.
DTAP Express	Feb-24	DTAP Express opened Singapore's first doctor-free sexual health testing clinic, incorporating customer-administered self-swab sample collection for sexually transmitted infection screenings. The alternative operational model prioritizes privacy and convenience while scaling accessibility to point-of-care diagnostics.
BD	Feb-23	BD secured U.S. FDA approval for its Onclarity HPV Assay, designed for use alongside the ThinPrep PAP test to detect specific human papillomavirus genotypes. This regulatory clearance expands advanced screening capabilities within the diagnostic portfolio, supporting enhanced detection of high-risk HPV types relevant to cervical cancer and STD diagnostics.